Umesh Shaligram

Mr. Umesh Shaligram, Director – Research & Development leads the development and manufacturing of several recombinant products like Hepatitis-B vaccine, HPV vaccine, CRM197, Acellular pertussis component based vaccine, Erythropoietin, Polysialylated Erythropoietin, Polysialic acid, r-BCG vaccine, GCSF and Pegylation of recombinant products as well as development of liposomal delivery at Serum Institute of India. His professional and educational background is in the process development of recombinant products and has experience in genetic engineering and bio-physics DNA structure and oligoneuclotides manufacturing during his studies from the Indian Institute of Science and also University of Pune. Serum Institute of India Private Ltd. (SIIPL) is the largest manufacturers of vaccines by number of doses produced and sold in the world. Over 1.3 billion vaccine doses are supplied worldwide by SIIPL. It is estimated that two out of every three children immunized in the world is vaccinated by at least one vaccine manufactured by Serum Institute. SIIPL’s range of products has been used in over 140 countries across the globe. Our products have been supplied to International Health Agencies like the WHO, UNICEF, PAHO and also to other countries across the globe. Serum Institute's commitment to global health is exemplified by significant investments in its infrastructure within India and in Europe. The R&D efforts are focused on developing vaccines that will meet the specific needs of different segments of the global population (e.g. development of Pandemic Influenza Vaccine) as well as on improving methods of vaccine delivery for its present range of vaccines viz. use of jet injectors, aerosol delivery, dry powder inhalation delivery etc. At SIIPL we believe in working collectively to manufacture, distribute and make available immunobiologicals which are safe, potent and efficacious for our customers, especially children of the world.